ArticleClinical and experimental immunology1999
Treatment of idiopathic CD4 T lymphocytopenia with IL-2.
Article in Clinical and experimental immunology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00001319 (Evaluation of the Epidemiology, Clinical Manifestations, Etiologies, and Immunology of Human Immunodeficiency Virus), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Epidemiology, Clinical Manifestations, Etiologies, and Immunology of Human Immunodeficiency Virus (HIV) Negative CD4 T Lymphocyte Deficient Patients
Who cites it
18 citing papers in PubMed, 64 citations in OpenAlex.
- Idiopathic CD4+ T-lymphocytopaenia withBMJ case reports · 2023Article
- Article
- Idiopathic CD4 lymphocytopenia: Pathogenesis, etiologies, clinical presentations and treatment strategies.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2017Article
- T-Cell Lymphopenia Detected by Newborn Screening in Two Siblings with an Xq13.1 Duplication.Frontiers in pediatrics · 2017Article
- A rare case of idiopathic cluster of differentiation 4(+) T-cell lymphocytopenia presenting with disseminated tubercular infection.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2015Article
- Idiopathic CD4 lymphocytopenia: clinical and immunologic characteristics and follow-up of 40 patients.Medicine · 2014Article
- PCP: thinking beyond HIV.BMJ case reports · 2013Article
- Idiopathic CD4 Lymphocytopenia: Spectrum of opportunistic infections, malignancies, and autoimmune diseases.Avicenna journal of medicine · 2013Article
- Altered responses to homeostatic cytokines in patients with idiopathic CD4 lymphocytopenia.PloS one · 2013Article
- [Lymphocytopenia: aetiology and diagnosis, when to think about idiopathic CD4(+) lymphocytopenia?].La Revue de medecine interne · 2012Article
- Idiopathic CD4 lymphocytopenia: a case of missing, wandering or ineffective T cells.Arthritis research & therapy · 2012Review
- Article
- Use of cytokine therapy in primary immunodeficiency.Clinical reviews in allergy & immunology · 2010Review
- Safety and efficacy of treatment using interleukin-2 in a patient with idiopathic CD4(+) lymphopenia and Mycobacterium avium-intracellulare.Clinical and experimental immunology · 2009Article
- Idiopathic CD4+ T-cell lymphocytopenia.Indian journal of pediatrics · 2009Article
- Article
- [Adult-onset primary immunodeficiencies].Der Internist · 2004Article
- Idiopathic CD4+ T-lymphocytopenia with bronchiectasis and hyperimmunoglobulin A.Annals of Saudi medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Idiopathic CD4 T lymphocytopenia (ICL) is an unusual immune defect in which there is an unexplained deficit of CD4 T cells, leading to fungal, parasitic or other serious opportunistic infections. Current treatment efforts are directed at eliminating infections. Here we describe the use of a novel treatment, subcutaneous polyethylene glycol (PEG)-IL-2 injections, in a woman with this disorder, who had chronic severe mycobacterial disease which led to repeated hospitalizations, and advancing respiratory insufficiency. For this patient, PEG-IL-2, 50 000 U/m2, has been given by weekly subcutaneous injections for 5.5 years. This treatment has resulted in marked (and still continuing) long-term immunological improvement with normalized T cell functions and increased CD4 cell numbers. She has had substantial clinical improvement with clearing of mycobacterial disease, reducing hospitalizations and improved lung functions. The improvement seen in this patient suggests that low-dose IL-2 is a safe and practical therapy, which might be useful in other subjects with this potentially serious immune defect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.